^
Association details:
| Biomarker: | PD-1 underexpression |
|---|---|
| Cancer: | Hodgkin Lymphoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Adcetris (brentuximab vedotin) (Microtubule inhibitor, CD30-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Baseline Tumor Transcriptome Characteristics Associated with the Response of Relapsed/Refractory Hodgkin Lymphoma Patients to Brentuximab Vedotin in Combination with Nivolumab
Published date:
11/01/2018
Excerpt:
Baseline tumor expression of CD30 above 16 counts per million mapped reads (CPM) was strongly associated with achieving CR after BV+Nivo (65% sensitivity and 93% specificity). CRs were associated with several other factors, including higher baseline tumor expression of macrophage markers CD14 and CD163 and lower expression of the Nivo target PD-1 (PDCD1) and multidrug resistance-associated protein 2 (MRP2/ABCC2) in the tumor microenvironment.
DOI:
10.1182/blood-2018-99-115481
Trial ID:
